ArticleNeurology2024
Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis: A Swedish Nationwide Study.
Article in Neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 42 citations in OpenAlex.
- [XVIII Post-ECTRIMS Meeting: Review of the New Developments Presented at the 2025 ECTRIMS Congress (Part II)].Revista de neurologia · 2026Article
- Association of Vitamin C Supplementation and Genetic Susceptibility with Multiple Sclerosis Risk: A Prospective Population-Based Cohort Study.Nutrients · 2026Article
- Brain atrophy rates vary with age in relapsing-remitting multiple sclerosis.Journal of neurology, neurosurgery, and psychiatry · 2026Article
- Insights into the therapeutic strategies for aging and aging-associated diseases.Signal transduction and targeted therapy · 2026Review
- Late-onset multiple sclerosis is associated with relapse-independent disability accrual: a propensity score-weighted recurrent-event study.Journal of neurology · 2026Article
- The burden and trends of late-onset multiple sclerosis, Parkinson's disease, Alzheimer's disease and other dementias among adults aged 55 and older, spanning from 1990 to 2021, with projections through 2050.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Multiple Sclerosis in Women: Impact of Different Life Stages on Treatment Decisions.CNS drugs · 2026Review
- Disability and Relapse Risk in Late-Onset Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.JAMA network open · 2026Article
- Differential Associations Between Perceived Social Support and Cognition in Older Adults With and Without Multiple Sclerosis.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2026Article
- Adult-onset and late-onset multiple sclerosis in older adults in a Finnish university hospital.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registry.Therapeutic advances in neurological disorders · 2026Article
- Menopause Impact on Multiple Sclerosis Disability Progression.JAMA neurology · 2025Article
- From youth to late age: a comparative analysis of clinical and demographic profiles in multiple sclerosis by age at onset.Postepy psychiatrii neurologii · 2025Article
- Late-onset myelin oligodendrocyte glycoprotein antibody-associated disease: an underrecognized entity in clinical practice; what does its course in later life teach us? A case report and narrative review.Postepy psychiatrii neurologii · 2025Article
- Severe attacks and worse prognosis in patients with late-onset neuromyelitis optica spectrum disorder highlight the need for early highly effective treatment.Journal of neurology · 2025Article
- Neural networks to estimate multiple sclerosis disability and predict progression using routinely collected healthcare data.Multiple sclerosis (Houndmills, Basingstoke, England) · 2025Article
- Effectiveness of Disease-Modifying Therapies in Patients With Late-Onset Relapsing-Remitting Multiple Sclerosis.Neurology · 2025Article
- Advancing multiple sclerosis management in older adults.Nature reviews. Neurology · 2025Article
- Deep Learning MRI Models for the Differential Diagnosis of Tumefactive Demyelination versusAJNR. American journal of neuroradiology · 2025Article
- Presence of cortical lesions in older persons with multiple sclerosis and association with cognitive function.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesClinical onset of multiple sclerosis (MS) after the age of 50 years is uncommon and associated with a less favorable natural history. The differences in long-term outcomes in patients with late-onset MS (LOMS, onset 50 years or older) and adult-onset MS (AOMS, onset 18 years or older and younger than 50 years) during the disease-modifying therapy (DMT) era have been less studied. This study aimed to compare patient characteristics, DMT exposure, and disability progression in Swedish patients with LOMS and AOMS over 2 decades (2001-2022).
methodsThe nationwide Swedish MS registry was searched for patients with an onset of MS between January 1, 2001, and December 31, 2018, with symptom onset at age 18 years or older and ≥2 recorded Expanded Disability Status Scale (EDSS) scores. Clinical and demographic parameters and exposure to DMT were compared between LOMS and AOMS. Time to disability milestones (EDSS 4 and 6) was assessed using Kaplan-Meier curves and Cox proportional hazards regression models adjusted for sex, disease course, calendar year at onset, and DMT exposure.
resultsAmong 8739 patients with MS who met inclusion criteria, 1,028 (11.8%) were LOMS. Primary progressive MS was more frequently diagnosed in LOMS compared with that in AOMS (25.2% vs 4.5%; DISCUSSION: This study distinguishes LOMS as a particularly vulnerable group and clinically supports close vigilance of these patients. Further studies are needed to assess and clarify the benefit of DMT usage in older adults with MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.